Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
31,382,476
-
Share change
-
-2,336,763
-
Total reported value
-
$157,240,505
-
Put/Call ratio
-
160%
-
Price per share
-
$5.01
-
Number of holders
-
73
-
Value change
-
-$10,626,389
-
Number of buys
-
32
-
Number of sells
-
26
Institutional Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q3 2022
As of 30 Sep 2022,
AVADEL PHARMACEUTICALS - COM (AVDL) was held by
73 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,382,476 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, GENDELL JEFFREY L, COWEN AND COMPANY, LLC, Vivo Capital, LLC, Polar Capital Holdings Plc, BRANDES INVESTMENT PARTNERS, LP, WEALTH EFFECTS LLC, RENAISSANCE TECHNOLOGIES LLC, Samsara BioCapital, LLC, and Modera Wealth Management, LLC.
This page lists
73
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.